Theralase Technologies Inc. V.TLT

1.3B$US for a 2030 drug

[ScienceFirst]

1.3B$US for a drug that will only reach commercialization in 2030 (in 7y) only.  This deal is to fasten its development. Obesity drugs are a hot topic these days.

https://www.reuters.com/markets/deals/novo-nordisk-acquire-obesity-drug-developer-inversago-2023-08-10/
 

Our treatment will be worth way more considering the fact that we're closer than that to commercialization (2026).  The fact that our data will also be 50% into a Ph. 2 will give us more value as the doubt is removed.  

So the waiting is worth it though in our case, that should be a jv for the moment, not a takeover, unless otherwise.

[Longholder99]

In our discussion about JV vs Takeover.  I wonder if all the holding back is in fact about maximizing value on RDW's terms for a complete buyout rather than JV.   He has to retire at some point.  He and Kristina have many millions of shares.  A 4 to 6B buyout would put the SP between 12 and 18 bucks a share depending on how much hype and the multiple you choose for

[ScienceFirst]

Longholder99 ... Dr. Mandel is older than Roger and not getting younger.  Clearly, TLT has to think about the future on the science side and ultimately getting bought after a Ph. 1b NSCLC and GBM is the plan. So it will be up to a big pharma to decide whether or not they want to buy us for the whole potential of our ACT platform or simply for a specific indication that suits their

[DJDawg]

RDW doesn't seem old to me. CEOs all seem to be older folks. I think this is a legacy deal for RDW. He wants to be part of something bigger in changing cancer care and helping develop a new sub-field of oncology. Making money would be fine too, but I don't see him rushing to seel and exit at all. IMO Dr. Mandel I can't speak to as he hasn't done any youtube interviews. :)